Drug Trial Radar · NCT02124278
Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Feb 2014
Primary completion
Oct 2014
Study completion Oct 2014
Sponsor
- Lead sponsor
- Pulmotect, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose is to determine if single doses of PUL-042 inhalation solution are safe in healthy subjects.
Conditions
- Healthy
Interventions
PUL-042 Inhalation SolutionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLTs)Time frame: Dosing to one week post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Development Solutions
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.